Tania Blanco-Martín

Tania Blanco-Martín

Auto-generated profile, based on publicly available information

Tania Blanco-Martín

Grupo de Investigación en Microbiología. Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña (CHUAC), Sergas, Universidade da Coruña

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2024 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
LGLucía González-Pinto
Lucía González-Pinto
IAIsaac Alonso-Garcia
Isaac Alonso-Garcia
TBTania Blanco-Martín
Tania Blanco-Martín
PCPablo Camacho-Zamora
Pablo Camacho-Zamora
PFPablo Arturo Fraile-Ribot
Pablo Arturo Fraile-Ribot
JAJorge Arca-Suarez
Jorge Arca-Suarez
We aimed to compare the stability of the newly developed β-lactams (cefiderocol) and β-lactam/β-lactamase inhibitor combinations (ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam/avibactam, cefepime/taniborbactam, cefepime/zidebactam, imipenem/relebactam, meropenem/vaborbactam, meropenem/nacubactam and meropenem/xeruborbactam) against the most clinically relevant mechanisms of mutational and transferable β-lactam resistance in Pseudomonas aeruginosa. We screened a collection of 61 P. aeruginosa PAO1 derivatives. Eighteen isolates displayed the most relevant mechanisms of mutational resistance to β-lactams. The other 43 constructs expressed transferable β-lactamases from genes cloned in pUCP-24. MICs were determined by reference broth microdilution. Cefiderocol and imipenem/relebactam exhibited excellent in vitro activity against all of the mutational resistance mechanisms studied. Aztreonam/avibactam, cefepime/taniborbactam, cefepime/zidebactam, meropenem/vaborbactam, meropenem/nacubactam and meropenem/xeruborbactam proved to be more vulnerable to mutational events, especially to overexpression of efflux operons. The agents exhibiting the widest spectrum of activity against transferable β-lactamases were aztreonam/avibactam and cefepime/zidebactam, followed by cefepime/taniborbactam, cefiderocol, meropenem/xeruborbactam and meropenem/nacubactam. However, some MBLs, particularly NDM enzymes, may affect their activity. Combined production of certain enzymes (e.g. NDM-1) with increased MexAB-OprM-mediated efflux and OprD deficiency results in resistance to almost all agents tested, including last options such as aztreonam/avibactam and cefiderocol. Cefiderocol and new β-lactam/β-lactamase inhibitor combinations show promising and complementary in vitro activity against mutational and transferable P. aeruginosa β-lactam resistance. However, the combined effects of efflux pumps, OprD deficiency and efficient β-lactamases could still result in the loss of all therapeutic options. Resistance surveillance, judicious use of new agents and continued drug development efforts are encouraged.

6 November 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
TBTania Blanco-Martín
Tania Blanco-Martín
ILInmaculada López-Hernández
Inmaculada López-Hernández
BABelén Aracil
Belén Aracil
LGLucía González-Pinto
Lucía González-Pinto
PAPablo Aja-Macaya
Pablo Aja-Macaya
O(on behalf of the GEMARA-SEIMC/CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT)
on behalf of the GEMARA-SEIMC/CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT)
We aimed to investigate the activity of and mechanisms of resistance to cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations in a nationwide collection of double-carbapenemase-producing Enterobacterales. In all, 57 clinical isolates co-producing two carbapenemases collected from Spanish hospitals during the period 2017–2022 were analyzed. Minimum inhibitory concentration (MIC) values for ceftazidime, ceftazidime/avibactam, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, cefiderocol, cefepime, cefepime/taniborbactam, cefepime/zidebactam, cefepime/nacubactam, imipenem, imipenem/relebactam, meropenem, meropenem/vaborbactam, meropenem/xeruborbactam, and meropenem/ANT3310 were determined by reference broth microdilution. Genetic drivers of resistance were analyzed by whole-genome sequencing (WGS). The collection covered nine carbapenemase associations: VIM + OXA-48 (21/57), NDM + OXA-48 (11/57), KPC + VIM (10/57), KPC + OXA-48 (6/57), IMP + OXA-48 (3/57), NDM + KPC (2/57), NDM + VIM (2/57), NDM + GES (1/57), and KPC + IMP (1/57). Ceftazidime/avibactam, imipenem/relebactam, and meropenem/vaborbactam were the least active options. Aztreonam/avibactam and aztreonam/nacubactam were active against the whole collection and yielded MIC 50 /MIC 90 values of ≤0.25/0.5 mg/L and 1/2 mg/L, respectively. Cefepime/zidebactam (56/57 susceptible), meropenem/xeruborbactam (56/57 susceptible), cefepime/nacubactam (55/57 susceptible), and cefiderocol (53/57 susceptible) were also highly active, with MIC 50 /MIC 90 values ranging from ≤0.25–2 mg/L to 2–4 mg/L, respectively. Meropenem/ANT3310 (MIC 50 /MIC 90 = 0.5/≥64 mg/L; 47/57 susceptible) and cefepime/taniborbactam (MIC 50 /MIC 90 = 0.5/16 mg/L; 44/57 susceptible) also retained high levels of activity, although they were affected by NDM-type enzymes in combination with porin deficiency. Our findings highlight that cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, nacubactam, taniborbactam, zidebactam, xeruborbactam, and ANT3310 show promising activity against double-carbapenemase-producing Enterobacterales.

19 March 2024 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
TBTania Blanco-Martín
Tania Blanco-Martín
IAIsaac Alonso-Garcia
Isaac Alonso-Garcia
LGLucía González-Pinto
Lucía González-Pinto
MOMichelle Outeda-García
Michelle Outeda-García
PGPaula Guijarro-Sánchez
Paula Guijarro-Sánchez
JAJorge Arca-Suárez
Jorge Arca-Suárez
To analyse the impact of the most clinically relevant β-lactamases and their interplay with low outer membrane permeability on the activity of cefiderocol, ceftazidime/avibactam, aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, imipenem/relebactam, meropenem/vaborbactam, meropenem/xeruborbactam and meropenem/nacubactam against recombinant Escherichia coli strains. We constructed 82 E. coli laboratory transformants expressing the main β-lactamases circulating in Enterobacterales (70 expressing single β-lactamase and 12 producing double carbapenemase) under high (E. coli TG1) and low (E. coli HB4) permeability conditions. Antimicrobial susceptibility testing was determined by reference broth microdilution. Aztreonam/avibactam, cefepime/zidebactam, cefiderocol, meropenem/xeruborbactam and meropenem/nacubactam were active against all E. coli TG1 transformants. Imipenem/relebactam, meropenem/vaborbactam, cefepime/taniborbactam and cefepime/enmetazobactam were also highly active, but unstable against most of MBL-producing transformants. Combination of β-lactamases with porin deficiency (E. coli HB4) did not significantly affect the activity of aztreonam/avibactam, cefepime/zidebactam, cefiderocol or meropenem/nacubactam, but limited the effectiveness of the rest of carbapenem- and cefepime-based combinations. Double-carbapenemase production resulted in the loss of activity of most of the compounds tested, an effect particularly evident for those E. coli HB4 transformants in which MBLs were present. Our findings highlight the promising activity that cefiderocol and new β-lactam/β-lactamase inhibitors have against recombinant E. coli strains expressing widespread β-lactamases, including when these are combined with low permeability or other enzymes. Aztreonam/avibactam, cefiderocol, cefepime/zidebactam and meropenem/nacubactam will help to mitigate to some extent the urgency of new compounds able to resist MBL action, although NDM enzymes represent a growing challenge against which drug development efforts are still needed.

5 December 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
TBTania Blanco-Martín
Tania Blanco-Martín
LGLucía González-Pinto
Lucía González-Pinto
PAPablo Aja-Macaya
Pablo Aja-Macaya
SRSalud Rodríguez-Pallares
Salud Rodríguez-Pallares
LSLucía Sánchez-Peña
Lucía Sánchez-Peña
GBGermán Bou
Germán Bou
Klebsiella pneumoniae carbapenemase (KPC) variants selected during ceftazidime/avibactam treatment usually develop susceptibility to carbapenems and carbapenem/β-lactamase inhibitors, such as imipenem and imipenem/relebactam. We analyzed imipenem and imipenem/relebactam single-step mutant frequencies, resistance development trajectories and differentially selected resistance mechanisms using two representative K. pneumoniae isolates that had developed ceftazidime/avibactam resistance during therapy (ST512/KPC-31 and ST258/KPC-35). Mutant frequencies and mutant prevention concentrations were measured in Mueller–Hinton agar plates containing incremental concentrations of imipenem or imipenem/relebactam. Resistance dynamics were determined after incubation for 7 days in 10 mL MH tubes containing incremental concentrations of each antibiotic or combination, up to 64 times their baseline MIC. Two colonies per strain from each experiment were characterized by antimicrobial susceptibility testing and whole genome sequencing. The impact of KPC variants identified in resistant mutants on β-lactam resistance was investigated by cloning experiments. Imipenem/relebactam suppressed the emergence of resistant mutants at lower concentrations than imipenem, slowed down resistance development for both strains, and the resulting mutants yielded lower MICs of carbapenems and carbapenem/β-lactamase inhibitors than those selected with imipenem alone. Characterization of resistant mutants revealed that imipenem resistance was mainly caused by inactivation of OmpK36 and mutations in the KPC β-lactamase. Imipenem/relebactam-resistant mutants also maintained OmpK36 alterations, but mutations in KPC were much less frequent compared with those selected with imipenem alone. Genetic and biochemical characterization of the KPC derivatives identified in the resistant mutants confirmed their role in carbapenem resistance. Our data positions imipenem/relebactam as an attractive therapeutic option for combating ceftazidime/avibactam-resistant KPC-producing K. pneumoniae infections.

17 September 2024 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
LGLucía González-Pinto
Lucía González-Pinto
TBTania Blanco-Martín
Tania Blanco-Martín
IAIsaac Alonso-Garcia
Isaac Alonso-Garcia
SRSalud Rodríguez-Pallares
Salud Rodríguez-Pallares
MOMichelle Outeda-García
Michelle Outeda-García
JAJorge Arca-Suarez
Jorge Arca-Suarez
We aimed to analyse the interplay between impaired iron uptake and β-lactamases on cefiderocol resistance in Pseudomonas aeruginosa. Thirty-one transferable β-lactamases and 16 intrinsic P. aeruginosa AmpC (PDC) variants were cloned and expressed in wild-type (PAO1) and iron uptake-deficient (PAO ΔpiuC) P. aeruginosa backgrounds. MICs of cefiderocol and antipseudomonal β-lactams were determined by reference broth microdilution. Relative to PAO1, deletion of piuC caused a specific 16-fold decrease in cefiderocol activity but negligible effects on the activity of other β-lactams. Among transferable β-lactamases, SHV-12, KPC Ω-loop mutants, NDMs and OXA-15 showed cefiderocol MIC values above the clinical breakpoint (2 mg/L) when expressed in PAO1. When expressed in PAO ΔpiuC, these and the transformants harbouring PER-1, VEB-1, KPC-2, KPC-3, VIM-1, CMY-2, OXA-2 and OXA-14 showed increased MIC values from 16 to >256 mg/L. The PDC variants carrying the Ω-loop changes ΔP215-G222 (PDC-577), E219K (PDC-221 and PDC-558) and the H10 helix change L293P (PDC-219) had the greatest impact on cefiderocol resistance, with MICs of 2–4 mg/L in PAO1 and of up to 32–64 mg/L in PAO ΔpiuC. Widespread enzymes such as GES, CTX-M-9, CTX-M-15, VIM-2-like enzymes, IMPs, DHA-1, FOX-4, OXA-10, OXA-48 and the other PDC variants tested had weaker effects on cefiderocol resistance. We add evidence about the effect of the interplay between iron uptake and β-lactamases on the acquisition of cefiderocol resistance in P. aeruginosa. These findings may help to anticipate the emergence of resistance and optimize the use of cefiderocol against P. aeruginosa infections.

2 December 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
PGPatricia García
Patricia García
PGPaula Guijarro
Paula Guijarro
CLCristina Lasarte-Monterrubio
Cristina Lasarte-Monterrubio
AMAndrea Muras
Andrea Muras
IAIsaac Alonso-García
Isaac Alonso-García
ABAlejandro Beceiro
Alejandro Beceiro
The rise in multidrug-resistant bacteria challenges clinical microbiology. Tigecycline, eravacycline, and omadacycline show promise against carbapenem-resistant Enterobacterales and Acinetobacter baumannii. This study evaluates their activity and resistance mechanisms. Two Spanish multicentre collections of WGS-characterized carbapenemase-producing Enterobacterales (n=399) and A. baumannii (n=118) were tested. The MICs of tigecycline, eravacycline, omadacycline and classic tetracyclines were determined. WGS-guided resistome analysis, expression studies, efflux pump inhibition and cloning assays identified potential mechanisms of resistance. Tigecycline and eravacycline exhibited the highest activity against the whole set of Enterobacterales (MIC50/MIC90 0.5/1 mg/L and 1/2 mg/L, respectively), and A. baumannii (MIC50/MIC90 1/2 mg/L and ≤0.25/1 mg/L, respectively). Omadacycline showed no improvement relative to classic tetracyclines (MIC50/MIC90 values of 8/32 mg/L and 8/16 mg/L for Enterobacterales and A. baumannii, respectively). Resistance mechanisms in Enterobacterales included efflux pumps (AcrAB-TolC, OqxAB) and mutation in their regulatory genes. In A. baumannii, adeS gene mutations and adeABC upregulation decreased tigecycline activity. The prevalent sequence types with reduced susceptibility to eravacycline and tigecycline were ST307 in K. pneumoniae and ST2 in A. baumannii. Eravacycline remains a key agent for the treatment of bacterial infections exhibiting promising efficacy against multidrug-resistant pathogens. As an empirical antibiotic it could be a good alternative for severe infections caused by CPE or CRAB, however, its clinical use is limited by the absence of standardized breakpoints. Resistance mechanisms, including efflux pumps and gene mutations, vary among isolates. High-risk clones like K. pneumoniae ST307 and A. baumannii ST2 underscore the necessity of prudent antibiotic use.